Search
Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15740Investigationalpotential for regenerative medicine. … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.
Categories: Experimental Unapproved Treatments for COVID-19Disulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalIt is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
Omega-6 fatty acids
go.drugbank.com/drugs/DB13168InvestigationalNutraceuticalThey are a family of fatty acid molecules that act as precursors to potent lipid mediator signalling molecules with either pro-inflammatory and anti-inflammatory effects.
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.
Bisoctrizole
go.drugbank.com/drugs/DB11262ApprovedBisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of … Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M [A19212].
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeαAβ–Gas6
go.drugbank.com/drugs/DB17069Experimental[A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the amyloid plaques found in individuals with AD and is considered to contribute to the pathophysiology … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD).
GTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.